IrelandA clinical trial involving 120 patients with advanced dementia found that a combination of THC and CBD from medical cannabis significantly reduced agitation in nearly 90% of participants after 12 weeks, compared to less than a quarter of those receiving a placebo. The study, presented at the Alzheimer’s Association International Conference, showed promise in managing a challenging symptom of dementia, though it has not yet been peer-reviewed. Experts note that current treatments like antipsychotics and opioids carry serious risks, making cannabinoids a potentially safer alternative. However, researchers caution that more research is needed, and the treatment should not be considered a cure-all due to potential risks associated with cannabis.
Bias read (Center): The article presents balanced coverage by including perspectives from multiple experts, including both proponents of the study and cautious voices like Dr. Kevin Hill. While the study's findings are highlighted, the article does not take a clear ideological stance and emphasizes the need for further
